ABVC BioPharma (ABVC) vs Incannex Healthcare (IXHL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ABVC BioPharma (ABVC) has outperformed Incannex Healthcare (IXHL) over the past year, losing 67.8% versus a loss of 80.3%. ABVC BioPharma is the larger company by market cap ($23.4 million vs $23.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVC | IXHL |
|---|---|---|
| Share price | $0.8663 | $1.86 |
| Market cap | $23.37M | $23.34M |
| 1-day change | -1.56% | +6.90% |
| YTD return | -59.33% | -82.68% |
| 1-year return | -67.80% | -80.32% |
| 5-year return | -97.29% | — |
| EPS (TTM) | $-0.20 | $-1.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $296.00K | $0 |
| Revenue growth (YoY) | -41.91% | -100.00% |
| Net income (latest FY) | $-7.91M | $-19.30M |
| Operating margin | -2415.97% | — |
| Net margin | -2671.81% | — |
| 52-week high | $2.87 | $14.91 |
| 52-week low | $0.707 | $1.61 |
| Distance from 52-week high | -69.82% | -87.53% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +904.30% |
| Average volume | 81.92K | 91.61K |
| Shares outstanding | 26.98M | 12.55M |
| Employees | 16 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABVC has outperformed IXHL by 12.5 percentage points over the past year.
- ABVC BioPharma grew revenue faster in its latest fiscal year (-41.91% vs -100.00%).
About ABVC BioPharma
ABVC stock →ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Incannex Healthcare
IXHL stock →Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
ABVC vs IXHL FAQ
Which is bigger, ABVC BioPharma or Incannex Healthcare?
ABVC BioPharma (ABVC) is larger, with a market capitalization of $23.37M compared with $23.34M for Incannex Healthcare (IXHL).
Which stock has performed better over the past year, ABVC or IXHL?
ABVC returned -67.80% over the past 12 months, compared with -80.32% for IXHL (price return, excluding dividends). Past performance does not predict future results.
Are ABVC BioPharma and Incannex Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.